Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.
N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.
N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
LRP4 antibody testing in myasthenia gravis.
Racke MK, Batish SD, Lisak RP, Barohn RJ.
J Neuroimmunol. 2022 Oct 15;371:577949. doi: 10.1016/j.jneuroim.2022.577949. Epub 2022 Aug 12.
Targeting T cell costimulation in autoimmune disease.
Stuart RW, Racke MK.
Expert Opin Ther Targets. 2002 Jun;6(3):275-89. doi: 10.1517/14728222.6.3.275.
Therapeutic potential of small interfering RNA for central nervous system diseases.
Lovett-Racke AE, Cravens PD, Gocke AR, Racke MK, Stüve O.
Arch Neurol. 2005 Dec;62(12):1810-3. doi: 10.1001/archneur.62.12.1810.
Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection.
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R.
Small Methods. 2023 Oct;7(10):e2300594. doi: 10.1002/smtd.202300594. Epub 2023 Jun 13.
Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings.
Goldschmidt C, Galetta SL, Lisak RP, Balcer LJ, Hellman A, Racke MK, Lovett-Racke AE, Cruz R, Parsons MS, Sattarnezhad N, Steinman L, Zamvil SS, Frohman EM, Frohman TC.
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 21;10(1):e200037. doi: 10.1212/NXI.0000000000200037. Print 2023 Jan.
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.
Li Y, Solis-Ruiz J, Yang F, Long N, Tong CH, Lacbawan FL, Racke FK, Press RD.
Blood Cancer J. 2023 Apr 24;13(1):59. doi: 10.1038/s41408-023-00833-7.
Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA.
Br J Haematol. 2015 Jul;170(2):200-7. doi: 10.1111/bjh.13422. Epub 2015 Apr 19.
Control of myeloid dendritic cell differentiation and function by CD1d-restricted (NK) T cells.
Racke FK, Clare-Salzer M, Wilson SB.
Front Biosci. 2002 Apr 1;7:d978-85. doi: 10.2741/racke.
